WE.SPEED.
On July 21, Moldovan Agency of Medicines and Medical Devices (AMDM, Agentia Medicamentelor si Dispozitivelor Medicale) has approved with priority review the first two clinical trials on COVID-19. The studies will include patients with moderate and/or severe condition.
Both clinical trials are conducted at the initiative of ARENSIA Exploratory Medicine in collaboration with the Republican Clinical Hospital "Timofei Moşneaga" with principal investigator Prof. Dr. Victor Cojocaru, Director of the Clinic for Anesthesiology and Intensive Therapy.
The first clinical trial will study a novel drug for the treatment of acute lung injury associated with COVID-19.
The second trial will study a novel investigational product, which has shown a promising antiviral activity against several human coronaviruses.
“It is a privilege to us and an opportunity as well that these large pharmaceutical companies dedicated to research, development and production of medicines from USA, EU and Canada have chosen the Republic of Moldova, along with other major countries, to conduct these clinical trials, with the purpose of development of effective drugs for the treatment of COVID-19 infection, from which our citizens will benefit too", said Mr. Eremei Priseajniuc, General Manager of AMDM.
“This is just the beginning!”, assures Dr. Nelea Ghicavîi, Country Manager of ARENSIA Exploratory Medicine Moldova, “At ARENSIA, we are working intensely on bringing more innovative treatments to Moldova.”
Claudia Hesselmann, CEO of ARENSIA Exploratory Medicine GmbH, Germany, highlights the importance of the contribution of AMDM, and in general of the Ministry of Health of the Republic of Moldova to attracting important research projects to Moldova: “The authorities of Moldova offer outstanding support for high quality clinical research. The speed of action of the Moldovan authorities under the urgency of COVID-19 is unrivalled!”
22.07.2020